國家衛生研究院 NHRI:Item 3990099045/12522
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856853      Online Users : 939
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12522


    Title: Validation of an EBV antibody risk stratification signature for nasopharyngeal carcinoma using multiplex serology
    Authors: Simon, J;Liu, Z;Brenner, N;Yu, KJ;Hsu, WL;Wang, CP;Chien, YC;Coghill, AE;Chen, CJ;Butt, J;Proietti, C;Doolan, DL;Hildesheim, A;Waterboer, T
    Contributors: National Institute of Cancer Research
    Abstract: Introduction: Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV) specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well-suited for comprehensive antigen selection, they are not applicable for large-scale studies.Methods: We have adapted a 13-marker EBV antigen signature for NPC risk identified by proteome arrays to multiplex serology, to establish an assay for large-scale studies. Taiwanese NPC cases (n=175) and matched controls (n=175) were used for assay validation. Spearman's correlation was calculated and the diagnostic value of all multiplex markers was assessed independently using the area under the receiver operating characteristic curve (AUC). Two refined signatures were identified using stepwise logistic regression, and internally validated with 10-fold cross validation.Results: Array and multiplex serology showed strong correlation for each individual EBV-marker, as well as for a 13-marker combined model on continuous data. Two refined signatures with either four (LF2 and BGLF2 IgG, LF2 and BMRF1 IgA) or two antibodies (LF2 and BGLF2 IgG) on dichotomous data were identified as the most parsimonious set of serological markers able to distinguish NPC cases from controls with AUCs of 0.992 (95% CI 0.983-1.000) and 0.984 (95% CI 0.971-0.997), respectively. Neither differed significantly from the 13-marker model (AUC = 0.992; 95% CI 0.982-1.000). All models were internally validated.Conclusion: Multiplex serology successfully validated the original EBV proteome microarray data. Two refined signatures of four and two antibodies were capable of detecting NPC with 99.2% and 98.4% accuracy.
    Date: 2020-04-23
    Relation: Journal of Clinical Microbiology. 2020 Apr 23;58(5):Article number e00077-20.
    Link to: http://dx.doi.org/10.1128/jcm.00077-20
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0095-1137&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000535797600002
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85084025047
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB32102852.pdf2252KbAdobe PDF229View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback